Kornimate/medical-research-clean huggingface dataset:
edge-to-edge mitral valve repair in the surgical treatment for hypertrophic cardiomyopathy

Conditions: Hypertrophic Obstructive Cardiomyopathy

Summary: objective of the study: to evaluate whether edge-to-edge technique improves clinical and hemodynamic results in patients scheduled to septal myectomy for severely symptomatic hypertrophic obstructive cardiomyopathy.

a randomised controlled pilot trial to evaluate whether edge-to-edge technique improves clinical and hemodynamic results in patients scheduled to septal myectomy for severely symptomatic hypertrophic obstructive cardiomyopathy. patients with proven hypertrophic cardiomyopathy and resting left ventricle outflow tract obstruction underwent septal myectomy. if patients were suitable for both surgical techniques, they were randomized to septal myectomy + edge-to-edge mitral valve repair or isolated septal myectomy. all surgeons were experienced at least 50 related procedures.

Eligibility criteria:
inclusion criteria: * provide written informed consent (either from the patient or a substitute decision-maker) * indications for surgical treatment (septal myectomy) of hypertrophic cardiomyopathy exclusion criteria: * indications for mitral valve replacement * patient failure at any stage of the study

Keywords: edge-to-edge repair mitral valve plastic (mvp) septal myectomy
nigella sativa in covid-19

Conditions: COVID-19; SARS-CoV-2

Summary: natural products with immunomodulation and antiviral activity showed a promising improvement in the outcomes of some viral infectious diseases both in preclinical and primitive clinical studies. the aim of this study is to utilize saudi fda licensed nigella sativa (ns) seed oil towards improving disease outcomes in adult patients diagnosed with mild covid-19. the study will be a prospective, open-label, non-randomized controlled pilot trial. patients will be supplemented (add-on) with one capsule of black seed oil twice daily for 10 days. the primary outcome will be the proportion of patients who clinically recovered on day 14. the secondary outcomes will be clinical parameters and routine laboratory tests. if encouraging outcomes occurred, ns supplementation may be recommended as an add-on to standard care protocol to enhance the recovery from covid-19 disease in the current emerging situation.


Eligibility criteria:
inclusion criteria: * patients with mild covid19 upper respiratory tract infection and with no evidence of pneumonia * adult (18 years and above) * written informed consent prior to initiation of any study procedures by the patient (or legally authorized representative). * understands and agrees to comply with planned study procedures. * has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by polymerase chain reaction (pcr) available at kauh. exclusion criteria: * patients with pneumonia or severe illness requiring admission to icu. * severe chronic kidney disease (i.e. estimated glomerular filtration rate (egfr) \< 30) or end stage renal disease requiring dialysis * sever chronic liver disease (alanine transaminase/aspartate transaminase (alt/ast) \> 5 times the upper limit of normal). * pregnancy or breast feeding. * anticipated transfer to another hospital which is not a study site within 72 hours. * allergy to any study medication.

Keywords: covid-19 sars-cov-2 nigella sativa herbal
the effect of use of dermal fat graft as a barrier membrane

Conditions: Unilateral Cleft Lip

Summary: a study conducted to assess the use of dermal fat graft use as barrier membrane over grafted bone

the study has two group in which the study will have in addition to the conventional bone grafting addition of dermal fat graft to protect the bone. the control will have just normal graft the results are assessed using computed tomography to assess the quality of the grafted bone. the chisquare test was used to asses the results significance.

Eligibility criteria:
inclusion criteria: patients having age range of 8-14ys who performed for 2ry alveolar cleft grafting at the ccc using adipose fat graft in conjunction with acbg boys or girls. unilateral or bilateral cleft alveolus. accepts healthy volunteers has not been entered. exclusion criteria: younger patients requiring 1ry grafting. older patients requiring 3ry grafting.

Keywords: alveolar cleft grafting
adalimumab (humira) in the treatment of refractory non-infectious uveitis

Conditions: Uveitis

Summary: the purpose of this study is to assess the safety and efficacy of adalimumab in uveitis.


Eligibility criteria:
inclusion criteria: 1. patients with vision-threatening autoimmune uveitis. 2. failure to respond to prednisone and at least one other systemic immunosuppressive (such as methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, or chlorambucil), or intolerance to such medications due to side effects. exclusion criteria: 1. serious concomitant illness that could interfere with the subject's participation in the trial. 2. previous or current use of cyclophosphamide. 3. unable or unwilling to undergo multiple injections.
effect of incentive spirometery on asthmatic pregnant women

Conditions: Asthmatic; Pregnant With Complication

Summary: the purpose of this study is to determine the effect of the incentive spirometer on asthma during pregnancy.

this study will provide an evidence basis for obstetricians and physical therapist for women's health about the effect of spirometry on asthma during pregnancy.

Eligibility criteria:
inclusion criteria: the patients will have the following criteria: 1. their age will range from 30 to40years old. 2. body mass index (bmi) will range from 25-29.9 kg/m2. 3. all patients will be clinically and medically stable. exclusion criteria: patients will be excluded from the study if they have the following: 1. diabetes mellitus. 2. severe hypertension. 3. neurological and neuromuscular disorders. 4. blindness. 5. developed moderate and severe degree of pleural effusion. 6. cardiovascular instability. 7. chronic chest disease.
food choice, psychological bias, and genetic predisposition

Conditions: Food Preferences; Genetic Predisposition; Psychological

Summary: this project aims to assess if food choice is impacted by loss aversion (la), and if this differs based on genetic predisposition to la, in a uk healthy cohort.

food choice, defined as how individuals decide on what to buy and eat, involves the acceptance and rejection of specific foods. food customisation is becoming more common amongst food retailers, allowing customers to alter their meals to their preferences by removing or adding items. today, food choice is viewed as more complex, food choices are not just dictated by taste but nutritional quality, allergens, and habits. for example, the framework provided for food customisation (e.g. pizza with toppings or a build you own pizza) and the perceived 'healthiness' of food items (e.g. the pizza toppings) can alter food choice. psychological reasoning, the process by which humans make decisions by drawing conclusions can play a role in food choice; however, humans can possess a psychological bias leading to illogical decision making. genetics can too play a role in decision making resulting in predetermined influence on food choice. this research wishes to determine if individual's genetics can affect their food choices by researching psychological biases to food choices.

Eligibility criteria:
inclusion criteria: * healthy (no known health condition) * 18 + years of age * uk based exclusion criteria: * vegetarian * vegan * other dietary pattern that restricts the consumption of animal products
novel coding strategies for children with cochlear implants

Conditions: Deafness

Summary: the purpose of this study is to understand performance with a cochlear implant. the long-term goals of this research are to improve sound perception with cochlear implants and to better understand the functioning of the auditory system. information from individuals with and without cochlear implants will be compared.

the overall objectives of this research are to 1) gain a better understanding of fundamental psychophysical abilities with electrical stimulation as a function of age (child vs adult), age at onset of deafness (pre- vs post-lingual), and acoustic hearing (normal vs limited or residual); and 2) determine whether manipulations in ci coding strategies will improve psychophysical and speech recognition outcomes for early implanted children. this work is expected to provide new insights into the corresponding improvements in perceptual outcomes to these newer strategies have been modest at best and performance has begun to level off.

Eligibility criteria:
inclusion criteria: * be 7 years of age or older and pre-lingually implanted with a cochlear implant (before the age of 2 years), have aided residual hearing, or have normal hearing. * be ages 18 or older and post-lingually implanted or have normal hearing. * be ages 18-35 and pre-lingually implanted. exclusion criteria: * any child implanted post-lingually
efficacy and safety of rivaroxaban in the management of acute non-neoplastic pvt compensated cirrhosis

Conditions: Portal Vein Thrombosis

Summary: -rivaroxaban is factor xa inhibitor

pvt is a common complication of liver cirrhosis

Eligibility criteria:
inclusion criteria: * acute pvt exclusion criteria: * malignant pvt * bleeding disorders
a study of mk-2060 in healthy participants (mk-2060-016)

Conditions: Venous Thrombosis

Summary: the goal of the study is to learn about the safety of mk-2060 and if people tolerate it when mk-2060 is given in different forms.


Eligibility criteria:
inclusion criteria: the key inclusion criteria include but are not limited to the following: * is in good health before randomization * has a body mass index (bmi) between ≥18 and ≤32 kg/m\^2, inclusive exclusion criteria: the key exclusion criteria include but are not limited to the following: * has a history of clinically significant endocrine, gastrointestinal (gi), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases * has a history of cancer
efficacy and safety of two atypical antipsychotics vs. placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: a study to evaluate the efficacy and safety of two atypical antipsychotics vs. placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder

this study was intended to compare the efficacy and safety of risperidone, quetiapine, and placebo in the treatment of patients with acute exacerbations of schizophrenia or schizoaffective disorder. the primary tested hypothesis was a comparison of the efficacy of risperidone and quetiapine (active combined group) to placebo. other a priori hypotheses tested included comparison of the onset of antipsychotic effect of risperidone to quetiapine and placebo, and to evaluate the efficacy, safety, and cost of risperidone compared with quetiapine in the treatment of subjects with an acute exacerbation of schizophrenia or schizoaffective disorder. during the first phase of the study (15 days), patients randomized to risperidone were titrated from 1 mg to 4 mg or from 1 mg to 6 mg per day, depending on body weight. patients randomized to quetiapine were titrated from 50 mg to 400 mg or from 50 mg to 600 mg per day, depending on body weight. based on investigators determination of patient clinical response, patients in the quetiapine group could be titrated to a maximum of 600 mg or 800 mg per day depending on body weight. during the second phase of the study (days 15 - 42), patients continue to take the dose of study medication taken in the first phase, but additional psychotropic medication could be added as clinically necessary to control symptoms in patients who remained sufficiently symptomatic (defined as a certain minimum value on a clinical global severity scale.)

Eligibility criteria:
current diagnosis of an acute exacerbation of either schizophrenia or schizoaffective disorder
the effect of testosterone replacement on bone mineral density in boys and men with anorexia nervosa

Conditions: Bone Metabolism

Summary: decreased bone strength is a common and serious medical problem present in many people with anorexia nervosa. men with anorexia nervosa have lower levels of gonadal steroids such as testosterone. low testosterone levels have been shown to result in low bone density. we are investigating whether bone mineral density and bone microarchitecture are abnormal in males with anorexia nervosa and whether supplementation with testosterone would improve both bone mineral density and bone microarchitecture.

low bone mineral density is a co-morbidity associated with anorexia nervosa that has been shown to persist even after weight gain. peak bone mass accrual occurs during the adolescent years, and a disruption in this critical process increases the risk for developing persistent deficits in bone density, and possibly increased fracture risk. multiple variables contribute to the bone mass accrual process in puberty including adequate levels of sex hormones and puberty specific changes in levels of these hormones. teenage boys with anorexia nervosa have lower bone density than normal weight boys of comparable maturity, and also have decreased levels of testosterone, as well as estradiol, when compared with healthy controls. although testosterone is an important predictor of bone density in males with anorexia nervosa, the effect of testosterone replacement on bone mass accrual and bone microarchitecture in hypogonadal teenage boys and young adult men with anorexia nervosa is unknown. we hypothesize both bone mass and bone microarchitecture are abnormal in anorexia nervosa and that testosterone replacement in adolescent males with anorexia nervosa will improve both bone mass and microarchitecture.

Eligibility criteria:
inclusion criteria: * anorexia nervosa * teenage boys and young adult men, age 14-30 years * hypogonadism indicated by a testosterone level within the lower 25th percentile for pubertal stage or below normal for pubertal stage exclusion criteria: * disease or illness known to affect bone metabolism * use of medications known to affect bone metabolism, such as corticosteroids or androgenic steroids, within 3 months of study initiation * subjects with a z-score less than -2.5 on dxa secondary to concerns of severely low bone mineral density which may require aggressive monitoring

Keywords: anorexia nervosa testosterone disordered eating hypogonadism bone
intraoperative radiation therapy in early stage breast cancer

Conditions: Breast Cancer

Summary: single arm study to assess the effectiveness of single dose intraoperative radiation therapy in patient with in situ and early stage breast cancer.

the purpose of this clinical study is to assess the effectiveness of iort, using an electronic brachytherapy system, in patients with limited-volume in situ and early stage breast cancer, with endpoints of: * local recurrence in early stage breast cancer patients treated with iort. * toxicity associated with iort. * long-term disease-specific and overall survival * cosmetic results using the harvard scale at start and follow-up periods in patients treated with iort. * quality of life in patients treated with iort. * health care costs associated with iort.

Eligibility criteria:
inclusion criteria: general inclusion criteria 1. age ≥ 45 years. 2. clinical stage tis, t1, t2 (≤ 3cm), n0, m0 (ajcc classification). 3. invasive ductal or lobular carcinoma, dcis and/ or pleomorphic lobular carcinoma in situ. exclusion criteria: 1. scleroderma, systemic sclerosis and active lupus. 2. participation in an investigational drug or device study. 3. previous ipsilateral radiation to the thorax or breast. 4. multifocal breast cancer. 5. pregnant patients. 6. patient not competent to provide informed consent. 7. neoadjuvant systemic therapy. 8. lymphovascular invasion on biopsy pathology

Keywords: iort breast cancer
bravo - betrixaban registry using real time observations in acute medical illness to assess venous thrombosis and bleeding outcomes

Conditions: Venous Thromboses

Summary: part 1 - evaluate the real-world implementation of extended prophylaxis with betrixaban in the acutely ill hospitalized medical population part 2 - describe patterns of venous thromboembolism (vte) prophylaxis in acutely ill medical patients who qualify for extended vte prophylaxis


Eligibility criteria:
inclusion criteria: -part 1 - 1. hospitalized acutely ill medical patient 2. patient prescribed betrixaban 3. signed informed consent part 2 - 1. hospitalized acutely ill medical patient 2. patient prescribed betrixaban or must satisfy criteria a and b: 1. moderately or severely restricted immobility: patient restricted to bed for at least 24 hours (severe) or restricted to bed for at least 12 hours (moderate) during their hospitalization 2. at least one additional risk factor: age \> 70 years d-dimer \> 2x institutional upper limit of normal (uln) obesity: body mass index (bmi) \> 30 kg/m2) history of pulmonary embolism (pe) or deep venous thrombosis (dvt) active cancer (diagnosed, treated, or progressing in the past 6 months) history of thrombophilia recent trauma or surgery (within 30 days prior to admission) ongoing hormonal treatment icu stay 3. signed informed consent exclusion criteria: * part 1 - 1. high bleeding risk - any of the following: 1. patient on dialysis 2. low platelet count (\<50 per 109/l) 3. known bleeding disorder (congenital or acquired) 4. liver disease prohibitive to anticoagulation 5. bleeding within last 30 days 6. use of dual anti-platelet therapy (dapt) part 2 1. patients who are on another oral anticoagulant (oac) for any reason at the time of hospitalization and will remain on it 2. condition requiring use of oac at admission, other than vte prophylaxis (eg, acute vte at admission) 3. high bleeding risk any of the following: 1. patient on dialysis 2. low platelet count (\<50 per 109/l) 3. known bleeding disorder (congenital or acquired) 4. liver disease prohibitive to anticoagulation 5. bleeding within last 30 days 6. use of dual anti-platelet therapy (dapt)
safe drug use in people with intellectual and/or developmental disabilities - it applies to life

Conditions: Disabilities, Intellectual; Disability, Developmental

Summary: the innovation idea is to develop valuable new knowledge about safe drug use in people with intellectual and/or developmental disabilities (idds). the main goal is to design a framework (routines and processes) that ensures safe drug use and provides qualitatively better services for people with idds. secondary goals are that employees will experience better security when working with medicines, and interact better with people with idd and relatives by implementing digital support functions. the innovation idea is specifically to develop/improve the following: 1) medication management: coordinating routines, procedures and work processes regarding all aspects of drug use, medication handling, and communication between care units for people with idds. 2) medication therapy: chart review of prescribed medication and gather knowledge about challenges related to drug use in this group. based on this, we will develop new methods for drug reconciliation and medication reviews to optimize drug use. 3) new framework for safe drug use in the community-based services for people with idds.

changing, developing, and testing new routines, procedures, and communication methods for safe drug use is challenging. the complexity of systems that are involved in medication management makes it particularly challenging to create well-designed digital solutions that ensure good working procedures. the complex issues faced by people with idds, as well as developments within personalized medicine, means that it is crucial to build new knowledge, work in teams, and arrange for medication reconciliation and medication reviews to be carried out regularly. furthermore, drug information must be provided, and adapted to the specific individual with an intellectual disability. in addition, the focus on personalized medicine means that the municipality must develop new guidelines for the use of pharmacogenetic tests so that the doctor can tailor drug selection and dosage to the individual patient.

Eligibility criteria:
inclusion criteria: * users of the municipality's service for people with disabilities exclusion criteria: -

Keywords: intellectual disabilities developmental disabilities intersectoral collaboration medication therapy management medication reconciliation medication review
chinese health investigation of nurse aging

Conditions: Lipid Depletion; Excessive Physical Exercise, Unspecified; Menopausal Syndrome

Summary: a follow-up intervention for the climacteric symptoms of nurses in peking

as we all know,hormone replacement therapy (hrt) is the main therapy to climacteric symptoms.but hrt has also some disadvantages including breast cancer,cardiovascular disease and so on, especially long period of hrt. it makes us to find the non-hormone therapy. so we want to investigate the exercise on the effect of climacteric symptoms.doing exercise is helpful for avoiding and treating many disease,including climacteric symptoms.in our previous research,we found that playing exercise can treat moderate climacteric symptoms.

Eligibility criteria:
inclusion criteria: * they are nurse ,aged40-55, lived in peking ,who are among perimenopausal women. exclusion criteria: -

Keywords: climacteric symptoms ; nurse ; intervention;follow-up